{"id":"NCT00849901","sponsor":"Eli Lilly and Company","briefTitle":"A Study in the Treatment of Children and Adolescents With Major Depressive Disorder","officialTitle":"A Double-Blind, Efficacy and Safety Study of Duloxetine Versus Placebo in the Treatment of Children and Adolescents With Major Depressive Disorder","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-03","primaryCompletion":"2011-03","completion":"2011-10","firstPosted":"2009-02-24","resultsPosted":"2012-03-06","lastUpdate":"2017-09-11"},"enrollment":337,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Major Depressive Disorder"],"interventions":[{"type":"DRUG","name":"duloxetine","otherNames":["LY248686","Cymbalta"]},{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"fluoxetine","otherNames":["LY110140","Prozac"]}],"arms":[{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Fluoxetine","type":"ACTIVE_COMPARATOR"},{"label":"Duloxetine","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to assess whether duloxetine is superior to placebo in the treatment of children and adolescents with major depressive disorder (MDD)","primaryOutcome":{"measure":"Change From Baseline in Children's Depression Rating Scale-Revised (CDRS-R) Total Score at Week 10 Endpoint","timeFrame":"Baseline, Week 10","effectByArm":[{"arm":"Duloxetine","deltaMin":-24.3,"sd":1.09},{"arm":"Fluoxetine","deltaMin":-23.7,"sd":1.06},{"arm":"Placebo","deltaMin":-24.3,"sd":1.11}],"pValues":[{"comp":"OG000 vs OG002","p":"0.999"}]},"eligibility":{"minAge":"7 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":25},"locations":{"siteCount":59,"countries":["United States","France","Germany","Russia","Slovakia","South Africa","Ukraine"]},"refs":{"pmids":["25978741","24813026","22699956"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":117},"commonTop":["Headache","Nausea","Nasopharyngitis","Vomiting","Decreased appetite"]}}